Egetis Therapeutics stock
EGTX.STSTOEgetis Therapeutics AB (publ), HealthcareISIN SE0003815604
42Score 42 out of 100, Weak
Price and trend
80 / 100
Price history
+80% in one yearThe chart shows daily closes over 16 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 65% above it.
Since April 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 86).
The price is at its 52-week high. Largest decline in 16 years: 95% (January 2016 to June 2022).
Chart figures for advanced users
- SMA 50$0.92
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$0.68
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)86
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$0.43
- The lowest closing price of the last twelve months.
- Resistance$1.12
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Egetis Therapeutics AB (publ) belongs to the Biotechnology industry (Sweden) and, with a market value of $520.6M, is number 242 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $6.28M (up 35.4% year on year) and a loss of $34.49M.
- For fiscal 2026, analysts expect on average revenue of $68.14M (up 984.5%) and adjusted earnings per share of $0.08.
Show more
- MEQIRI Score 42 out of 100 (Weak): rank 520 of 714 in Healthcare, median 53.
- Our model puts fair value at $0.52, with the price 115% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $26.83M, financial debt $7.09M.
Weaknesses
- DilutionShare count up 401% since 2020.Capital allocation 18
- Above fair valuePrice 115% above the fair value of $0.52.Valuation 21
- Loss-makingLoss of $47.33M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 43 to 42.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- price up very strongly over the past year
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $0.37 and expensive above $0.87 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 7.4%. At 8.4% the fair value would be $0.48, at 6.4% it would be $0.57.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 26.7% on the twelve months before. Revenue has grown strongly since 2017, at around 21% per year. From 2017 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 20%, operating −556%, net −549%. Last 12 months: net −100%. From 2017 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 5 Nov 2026EPS reported −$0.02 (expected −$0.02)below expectations
Analyst estimates
- Earnings per share
- $0.08+3.7%
- Revenue
- $68.14M+1.5%
- Earnings per share
- $0.000.0%
- Revenue
- $60.71M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Egetis Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 42
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Crescent BiopharmaCBIO $548.24M33
- Ovid TherapeuticsOVID $542.93M44
- Eupraxia PharmaceuticalsEPRX $532.55M44
- DiaMedica TherapeuticsDMAC $520.92M46
- Shattuck LabsSTTK $514.3M31
- Phathom PharmaceuticalsPHAT $510.51M29
- Avalo TherapeuticsAVTX $492.07M34
- MiMedx GroupMDXG $484.47M37
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = SEK 9.9317)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Mar 2012)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.